Back to Agenda
Session 4: Quantifying the Impact of Patient Engagement
Session Chair(s)
Kenneth Getz, MBA
Tufts Center for the Study of Drug Development
Center For the Study of Drug Development, United States
There is growing consensus among stakeholders in the medical product life cycle that patient engagement is critical to assuring that patient needs -- including those associated with clinical trial participation and with patient outcomes, are met. The moral, ethical, and pragmatic reasons for patient engagement are widely accepted, but research sponsors are also looking to understand the impact of patient engagement on study timelines and costs and on overall program success. Understanding return on investment, or return on engagement (ROE), is complicated by the availability of many different types of patient engagement efforts that could be employed and the lack of information about their value in a given context.
Presenters in this session will discuss the results of recent retrospective and prospective studies quantifying the return on patient engagement. This session will also explore the importance of establishing consensus metrics to measure and benchmark ROE.
Learning Objective :
Speaker(s)
Speaker
Stella Stergiopoulos, MPH, MS
EQRx, United States
Director, Health Economic and Outcomes Research
Speaker
Kenneth Getz, MBA
Center For the Study of Drug Development, United States
Tufts Center for the Study of Drug Development
Speaker
Linda B Sullivan, MBA
Tufts Center For the Study of Drug Development, United States
Senior Fellow
Have an account?